Clinical Outcomes Data
Real-time analytics from MindScape Retreat's Kratom Dependency Protocol program. Aggregated across 50 patients with 2,100+ individual clinical assessments tracked over 7 timepoints.
Our clinical database tracks each patient's withdrawal trajectory in real-time across seven validated assessment timepoints. What makes kratom dependency pharmacologically distinct is the dual alkaloid profile, mitragynine provides sedative-opioid effects at lower doses, while 7-hydroxymitragynine (7-OH), present in high concentration in commercial extracts, produces potent mu-opioid receptor agonism that rivals classical opioids in binding affinity. This distinction required that withdrawal tracking instruments be applied with attention to kratom's unique receptor pharmacology rather than assuming a one-to-one correspondence with heroin or prescription opioid withdrawal profiles.
The following interactive dashboard presents aggregated outcomes from all 50 patients in the kratom dependency cohort, combining data across both conventional powder users (n=32) and high-potency 7-OH extract users (n=18). The real-time trajectory analysis enables direct visualization of treatment response across withdrawal severity, craving, pain, sleep quality, and overall wellbeing, dimensions that are all clinically affected by kratom dependency and that all show measurable improvement following ibogaine-assisted detoxification.
The trajectory patterns in this cohort reflect kratom's pharmacologically distinct withdrawal profile. Unlike classical opioids, where the withdrawal curve typically peaks within 24 to 72 hours and resolves within a week, kratom withdrawal, particularly in extract users, can exhibit a prolonged course driven by mitragynine's comparatively long half-life and the broader spectrum of receptor targets it engages beyond the mu-opioid system. Despite this complexity, ibogaine's multi-receptor mechanism produces withdrawal suppression within the same early timeframe observed in classical opioid protocols.
The dashboard trajectories demonstrate that improvement is sustained through and beyond the noribogaine depot phase. the 4 to 6 week window during which noribogaine, ibogaine's primary active metabolite, provides low-level receptor modulation from adipose tissue stores. This sustained activity is clinically critical for kratom patients because the post-cessation anhedonia and insomnia that characterize kratom withdrawal, and that reliably drive relapse, require weeks rather than days to fully resolve through neurobiological repair.
Study Overview
50 Patients. Kratom Powder, Extracts, and 7-OH Concentrate. One Reset Protocol.
This cohort study enrolled 50 patients presenting with physical dependency on kratom (Mitragyna speciosa) in its various formulations: traditional powder, enhanced-leaf preparations, and high-potency 7-hydroxymitragynine (7-OH) extracts. Average daily kratom dose at enrollment was 40 to 80 grams of powder equivalent, with extract users often consuming products containing the equivalent of several hundred milligrams of 7-hydroxymitragynine.
The cohort reflected the common progression trajectory of kratom dependency: many patients had escalated from modest powder use to commercial extracts or pure 7-OH concentrate over 12 to 36 months as tolerance developed. Multiple prior quit attempts were documented in 78% of patients, with the majority reporting failure due to withdrawal severity and post-cessation anhedonia.
Outcomes were tracked using validated clinical instruments across the full dependency cycle: Clinical Opiate Withdrawal Scale (COWS) and Subjective Opiate Withdrawal Scale (SOWS) for withdrawal severity, and Visual Analogue Scales for craving (VAS_CRAVING), pain (VAS_PAIN), sleep (VAS_SLEEP), and wellbeing (VAS_WELLBEING) across the treatment and follow-up period.
Quantifying withdrawal severity in kratom-dependent patients requires both objective and subjective measurement. The Clinical Opiate Withdrawal Scale (COWS) captures the clinician-observed physiological signs, pulse rate, sweating, restlessness, pupil dilation, gastrointestinal symptoms, tremor. that map directly onto mu-opioid receptor withdrawal regardless of whether the precipitating substance was heroin, prescription opioids, or kratom alkaloids. The Subjective Opiate Withdrawal Scale (SOWS) complements this by capturing the patient's own experience of withdrawal: the anxiety, muscle aching, insomnia, and dysphoria that drive continued use.
Baseline kratom withdrawal scores in this cohort, while lower than those observed in fentanyl or heroin patients, nonetheless fall in the moderate clinical range, consistent with published characterizations of kratom withdrawal syndrome as comparable in severity to a moderate-intensity classical opioid withdrawal. The following chart illustrates the magnitude and speed of withdrawal reduction following ibogaine administration.
Withdrawal Severity. Baseline vs. Post-Treatment
COWS (Clinical Opiate Withdrawal Scale, 0 to 48) and SOWS (Subjective Opiate Withdrawal Scale, 0 to 64) measure objective and subjective withdrawal severity respectively. Lower scores indicate reduced withdrawal burden. Values represent cohort averages at post-treatment assessment.
Source: MindScape Retreat Kratom Dependency Cohort Study (n=50), post-treatment assessment.
The COWS and SOWS reductions documented above confirm that ibogaine successfully interrupts the neurophysiological withdrawal syndrome at both the objective and subjective level. However, withdrawal suppression alone does not account for kratom dependency's full clinical burden. A defining feature of kratom use. particularly among long-term daily users, is that the substance is often being used to manage chronic pain, profound fatigue, and emotional distress. When kratom is removed, these underlying conditions re-emerge alongside withdrawal, creating a multi-dimensional burden that goes well beyond the opioid-receptor-mediated symptoms captured by COWS and SOWS.
The following chart examines three domains that extend beyond withdrawal severity into functional quality of life: craving intensity, pain, and sleep quality. Together they provide a more complete account of what ibogaine actually restores in kratom-dependent patients, and why so many describe the post-treatment period as a qualitative improvement over baseline, not merely an absence of withdrawal.
Quality of Life Measures. Baseline vs. Post-Treatment
Visual Analogue Scale scores (0 to 100 for craving and pain; 0 to 10 for sleep quality) assessed at baseline and post-treatment. For craving and pain, lower scores indicate improvement. For sleep quality, higher scores indicate improvement. Values represent cohort averages.
Source: MindScape Retreat Kratom Dependency Cohort Study (n=50), VAS assessments at baseline and post-treatment.
Taken together, the withdrawal severity data and the quality-of-life measures present a coherent clinical narrative: ibogaine does not simply suppress withdrawal symptoms, it resets the neurobiological systems that kratom dependency has chronically disrupted. The 87% reduction in craving (VAS 78 to 10) demonstrates that the compulsive drive to use is interrupted at the receptor level by noribogaine. The 72% reduction in pain (VAS 65 to 18) reflects ibogaine's analgesic properties alongside the normalization of pain sensitivity that becomes dysregulated during chronic mu-opioid receptor downregulation. The improvement in sleep quality from 3.2 to 8.1 on a 0 to 10 VAS (72% of achievable improvement) is among the most clinically significant single findings in this dataset.
Sleep normalization is of particular prognostic importance in kratom recovery because insomnia is the symptom most frequently cited by patients who relapse. the inability to sleep without kratom drives return to use within days of cessation in a substantial proportion of unassisted quit attempts. The speed and magnitude of sleep quality improvement observed here, beginning within 72 hours of treatment, provides a protective buffer through the most vulnerable early-abstinence period. These combined findings are detailed further in the key clinical outcomes section below.
Prospective Observational Cohort Study
Study Design
Prospective, single-center observational cohort study with 90-day longitudinal follow-up. Stratified enrollment by kratom formulation type: conventional powder users (n=32) and concentrated 7-hydroxymitragynine extract users (n=18). Written informed consent obtained from all participants.
Inclusion Criteria
Adults aged 18 to 55 with kratom dependency of ≥ 6 months duration. Daily kratom consumption ≥ 20g powder equivalent. Cardiac clearance (QTc < 450ms). Hepatic function within acceptable parameters (AST/ALT < 3× ULN). Prior quit attempt(s) with documented failure due to withdrawal severity or relapse.
Assessment Instruments
Primary: COWS (0 to 48) and SOWS (0 to 64) for withdrawal severity. Secondary: VAS Craving (0 to 100), VAS Pain (0 to 100), VAS Sleep Quality (0 to 10, higher = better), VAS Wellbeing (0 to 100, higher = better). All instruments validated for opioid-type withdrawal assessment, applicable to kratom's mu-opioid receptor mechanism.
Assessment Schedule
Seven standardized timepoints: Baseline (admission), 24h post-ibogaine, 72h post-ibogaine, Day 7, Day 14 (discharge), Day 30, Day 60, and Day 90 follow-up. Remote follow-up via secure telehealth platform with self-report verification.
Subgroup Analysis
Pre-specified subgroup analysis comparing powder users (n=32) versus 7-OH extract users (n=18) across all primary and secondary endpoints. Extract users defined as daily consumption of commercial products containing concentrated 7-hydroxymitragynine. Between-group comparisons using independent t-tests with Bonferroni correction.
Safety Monitoring
Continuous cardiac telemetry during ibogaine administration. Hepatic function monitoring at baseline, Day 3, Day 7, and Day 14 given kratom's documented hepatotoxicity potential. All adverse events coded per MedDRA and reviewed by attending physician within 24 hours.
Mechanism of Action
Why Ibogaine Is Effective for Kratom Addiction
Kratom's primary active alkaloids, mitragynine and 7-hydroxymitragynine, act as partial agonists at the mu-opioid receptor. the same receptor targeted by morphine, oxycodone, and heroin. While mitragynine's receptor affinity is relatively modest, 7-hydroxymitragynine binds with potency that rivals and in some formulations exceeds classical opioids. Chronic exposure downregulates mu-opioid receptor expression, reduces endogenous opioid tone, and suppresses dopaminergic reward signaling. producing a neurological deficit that drives continued use and makes abstinence acutely dysphoric.
Ibogaine's mechanism addresses kratom dependency across multiple dimensions simultaneously. Its direct action at mu-opioid receptors through noribogaine (ibogaine's long-acting primary metabolite) maintains receptor occupancy in the days following treatment, effectively bridging the withdrawal period without the patient experiencing the typical severity of the kratom cessation syndrome. This is not substitution therapy, noribogaine's binding profile is distinct from kratom alkaloids and does not perpetuate the dependency cycle.
At the neuroplasticity level, ibogaine upregulates glial cell line-derived neurotrophic factor (GDNF), which drives repair of dopaminergic neurons damaged or suppressed by chronic kratom use. The profound post-kratom anhedonia. the absence of pleasure that makes early abstinence so difficult to sustain, is mechanistically linked to dopaminergic pathway suppression. GDNF-mediated dopamine system repair directly targets this deficit, producing the mood normalization that patients describe as qualitatively different from any prior quit attempt.
7-OH Extract Challenge
When Kratom Escalates: The 7-Hydroxymitragynine Extract Problem
7-hydroxymitragynine (7-OH) is the alkaloid responsible for kratom's most potent opioid effects. Research published in the Journal of Medicinal Chemistry and confirmed by subsequent pharmacological studies has established that 7-OH is approximately 13 times more potent than morphine at the mu-opioid receptor. Commercial kratom extract products, increasingly sold in convenience stores, gas stations, and online. often concentrate 7-OH far beyond levels found in natural kratom leaf, creating a dependency profile that substantially exceeds what the term 'kratom user' has historically implied.
Patients presenting with 7-OH extract dependency typically require a modified ibogaine protocol compared to those using conventional kratom powder. Their receptor downregulation is more pronounced, their withdrawal severity scores at baseline are higher, and the psychological dependency. often developed more rapidly due to the extract's reinforcing potency, requires additional attention during the integration phase of treatment.
Despite the increased complexity of the 7-OH extract presentation, cohort outcomes remained highly favorable. Withdrawal score reductions were comparable to those seen in powder users, and 90-day abstinence rates for extract users (89%) were marginally lower but not statistically significantly different from powder users (94%). Our medical director's protocol modifications, including adjusted ibogaine dosing and extended monitoring periods, successfully accommodated the more demanding clinical profile of this subgroup.
Principal Findings From 50-Patient Kratom Cohort
92% of patients (n=46/50) were confirmed kratom-free at 90-day follow-up via self-report with collateral verification, establishing ibogaine as a viable single-session intervention for kratom dependency. a condition with no FDA-approved pharmacological treatment.
Mean COWS reduction of 86% (baseline 22.4 ± 3.8 → post-treatment 3.1 ± 1.9, p < 0.001). Withdrawal interruption occurred within 4 to 8 hours of ibogaine administration, consistent with noribogaine's rapid mu-opioid receptor engagement.
7-hydroxymitragynine extract users (n=18) achieved 89% abstinence at 90 days versus 94% for powder users (n=32). The difference was not statistically significant (p = 0.42), suggesting ibogaine's mechanism effectively addresses both conventional and high-potency kratom dependency.
Sleep quality improved from 3.2 to 8.1 on a 0 to 10 VAS (72% of achievable improvement), with patients reporting the most dramatic sleep normalization in the first 72 hours. an outcome with significant clinical relevance given that insomnia is the primary driver of kratom relapse.
VAS Pain scores decreased 72% (65.3 → 18.2), confirming that ibogaine addresses the chronic pain component that frequently underlies and sustains kratom dependency. Noribogaine's analgesic properties may contribute to this effect beyond the opioid receptor reset.
No hepatic adverse events were recorded despite 34% of the cohort presenting with mildly elevated baseline liver enzymes (ALT > 40 U/L). Post-treatment hepatic panels at Day 14 showed normalization trends in all patients, suggesting ibogaine did not compound kratom-related hepatic stress.
Clinical Protocol
10 to 14 Day Kratom Detox Protocol
Medical Screening Including Liver Function Panel
All kratom candidates undergo comprehensive bloodwork with particular attention to hepatic function markers. Kratom has documented hepatotoxicity potential, and elevated liver enzymes. particularly ALT and AST, are not uncommon in long-term daily users. Liver function assessment is mandatory before ibogaine administration, as ibogaine is hepatically metabolized and baseline hepatic status directly informs safe dosing parameters. EKG cardiac screening and a full medication interaction review are completed at this stage.
Supervised Taper from Extracts to Plain Leaf
Patients presenting on high-potency 7-OH extracts or concentrated kratom products complete a supervised pre-treatment taper from commercial extracts to standardized plain-leaf powder. This step reduces the receptor occupancy profile to a more predictable baseline, optimizes ibogaine's ability to achieve full receptor displacement, and reduces the risk of unpredictable pharmacokinetic interactions during the treatment session. Our medical team manages all taper protocols remotely prior to the patient's arrival in Cozumel.
Custom Ibogaine Dosing for Kratom Dependency
Our medical director designs a personalized ibogaine dosing protocol specific to each patient's kratom history: daily dose, formulation type (powder vs. extract), duration of use, current hepatic function, body weight, and any comorbid psychiatric conditions. Kratom dependency protocols typically use Ibogaine HCl for precision dosing, with optional Total Alkaloid extract supplementation for patients whose dependency includes significant mood and anxiety dimensions requiring broader alkaloid spectrum coverage.
Treatment at MindScape Retreat with Continuous Monitoring
Ibogaine is administered at our medically-equipped sanctuary on Cozumel Island under continuous physician and nursing supervision. Cardiac telemetry monitoring runs throughout the treatment session and initial recovery period. For kratom patients, the most commonly reported immediate post-treatment experience is the unexpected absence of withdrawal. the suffering that prior quit attempts invariably produced simply does not materialize. Most patients are ambulatory and appetite-restored within 24 to 36 hours of treatment completion.
Integration Therapy and 90-Day Aftercare Framework
Every patient departs with a written 90-day aftercare plan tailored to their specific kratom history and treatment experience. Integration addresses both the physiological recovery arc, rebuilding natural dopamine function through nutrition, exercise, and sleep discipline, and the psychological dimension of dependency: understanding the role kratom played in managing anxiety, energy deficits, or emotional pain, and developing alternative strategies for those underlying needs. Scheduled check-ins at 30, 60, and 90 days are included for all patients.
Frequently Asked Questions
Questions About Ibogaine for Kratom Addiction
Supporting Literature & Citations
Freedom From Kratom Dependence Is Achievable
Our medical team evaluates every candidate individually, taking kratom dependency with the clinical seriousness it deserves. Whether you use powder or high-potency extracts, we will review your history honestly and tell you whether ibogaine is the right path for you.
Request a Confidential Evaluation